ArticleDrug and alcohol review2025
Contents and Time-Course of Falsified Alprazolam Detections in New South Wales, Australia.
Article in Drug and alcohol review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026Review
- The Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction-A Narrative Review.Drug and alcohol review · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFalsified alprazolam tablets (sometimes called 'counterfeit alprazolam') typically do not contain alprazolam and instead contain novel benzodiazepines or other drugs. We describe temporal changes in the number and contents of falsified alprazolam tablets in New South Wales, Australia.
methodsWe searched a database of analysed police seizures between January 2012 and March 2024 for falsified alprazolam (tablet presenting as Kalma, Mylan, Xanax, Sandoz or Alprax brands, but not containing alprazolam and/or contained other drugs). Falsified alprazolam tablets taken by patients presenting to NSW Health services for 5 months in 2020 were also tested.
resultsWe identified 809 falsified alprazolam tablet seizures, mostly Xanax (n = 406, 50%) or Mylan (n = 322, 40%) brands. The three most common drugs detected in falsified alprazolam tablets were the novel benzodiazepines etizolam (present in n = 228 samples, 28%), clonazolam (n = 224, 28%) and bromazolam (n = 178, 22%). Of all falsified alprazolam tablets, only 70 (8.7%) contained alprazolam. There were rare detections of non-benzodiazepine drugs including the opioids etodesnitazene and ortho-desmethyltramadol. DISCUSSION AND
conclusionsOur analysis highlights the variability in contents of falsified alprazolam tablets over time. This report highlights the potential value of surveillance systems involving analysis of police seizure data as part of a drug early warning system. Our results are of interest to the community who take falsified alprazolam tablets, and to health care workers managing cases of poisoning or dependence. This study highlights the need to continue developing the ability to detect, assess and respond to emerging falsified products, to facilitate clinical and public health responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.